Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial

Discusses how 20-70% of patients with active tuberculosis in Africa are co-infected with HIV, and mortality among these patients is high, even after tuberculosis is cured. Finds that, in HIV-1-infected patients with tuberculosis, daily trimethoprim-sulphamethoxazole (co-trimoxazole) prophylaxis was...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) Vol. 1; pp. 1469 - 1475
Main Authors:	Wiktor, S Z, Sassan-Morokro, M, Grant, A D, Abouya, L, Karon, J M, Maurice, C, Djomand, G, Ackah, A
Format:	Journal Article
Language:	English
Published:	01-05-1999
Subjects:	Abidjan Bacterial infection Human immunodeficiency virus Ivory Coast Patients Randomized controlled trials Tuberculosis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Discusses how 20-70% of patients with active tuberculosis in Africa are co-infected with HIV, and mortality among these patients is high, even after tuberculosis is cured. Finds that, in HIV-1-infected patients with tuberculosis, daily trimethoprim-sulphamethoxazole (co-trimoxazole) prophylaxis was well tolerated and significantly decreased mortality and hospital admission rates. Suggests that these findings may have important implications for improvement of clinical care for such patients in Africa. (Original abstract - amended)
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 content type line 23 ObjectType-Feature-2
ISSN:	0140-6736